Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results.

Subgroup analyses of ACR response rate, EULAR response, and proportion of patients with low disease activity and remission (according to the DAS28, SDAI, and CDAI) showed a trend toward decreased efficacy in antidrug antibody–positive patients (n = 84) compared with antidrug antibody–negative patients (n = 423) in all treatment groups (see Supplementary Table 1 , http://onlinelibrary.wiley.com/doi/10.1002/art.40444/abstract ).

also in 53,322 other papers